NASDAQ:NKTR Nektar Therapeutics (NKTR) Stock Price, News & Analysis $1.26 -0.04 (-3.08%) (As of 09/18/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Nektar Therapeutics alerts: Email Address About Nektar Therapeutics Stock (NASDAQ:NKTR) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Nektar Therapeutics alerts:Sign Up Key Stats Today's Range$1.25▼$1.3250-Day Range$1.11▼$1.4852-Week Range$0.41▼$1.93Volume634,448 shsAverage Volume1.82 million shsMarket Capitalization$231.87 millionP/E RatioN/ADividend YieldN/APrice Target$1.50Consensus RatingHold Company OverviewNektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.Read More… Central Bank Abandons USD (Ad)Startling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold. Click here now to get your free 'Protect Your Wealth' Guide. Nektar Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 78th PercentileNektar Therapeutics scored higher than 78% of companies evaluated by MarketBeat, and ranked 236th out of 1,017 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.1 / 5Analyst RatingHold Consensus RatingNektar Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 2 buy ratings, 2 hold ratings, and 1 sell rating.Amount of Analyst CoverageNektar Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Nektar Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Nektar Therapeutics are expected to grow in the coming year, from ($0.85) to ($0.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nektar Therapeutics is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nektar Therapeutics is -1.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNektar Therapeutics has a P/B Ratio of 1.83. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Nektar Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.63% of the float of Nektar Therapeutics has been sold short.Short Interest Ratio / Days to CoverNektar Therapeutics has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Nektar Therapeutics has recently decreased by 2.72%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldNektar Therapeutics does not currently pay a dividend.Dividend GrowthNektar Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.2 / 5Environmental Score-1.77 Percentage of Shares Shorted4.63% of the float of Nektar Therapeutics has been sold short.Short Interest Ratio / Days to CoverNektar Therapeutics has a short interest ratio ("days to cover") of 5.2.Change versus previous monthShort interest in Nektar Therapeutics has recently decreased by 2.72%, indicating that investor sentiment is improving. News and Social Media3.3 / 5News Sentiment0.94 News SentimentNektar Therapeutics has a news sentiment score of 0.94. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Nektar Therapeutics this week, compared to 2 articles on an average week.Search Interest3 people have searched for NKTR on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat Follows2 people have added Nektar Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Nektar Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $27,836.00 in company stock.Percentage Held by InsidersOnly 3.71% of the stock of Nektar Therapeutics is held by insiders.Percentage Held by Institutions75.88% of the stock of Nektar Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Nektar Therapeutics' insider trading history. Receive NKTR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nektar Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NKTR Stock News HeadlinesNektar Therapeutics (NASDAQ:NKTR) CEO Howard W. Robin Sells 14,881 SharesAugust 21, 2024 | insidertrades.comAnalysts Set Nektar Therapeutics (NASDAQ:NKTR) PT at $1.50September 14, 2024 | americanbankingnews.comCentral Bank Abandons USDStartling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold. September 18, 2024 | True Gold Republic (Ad)Nektar Management to Present at Upcoming Investor ConferencesSeptember 3, 2024 | prnewswire.comNektar Therapeutics (NASDAQ:NKTR) Stock Quotes, Forecast and News SummaryAugust 27, 2024 | benzinga.comNektar Therapeutics (NKTR) Q2 2024 Earnings Call TranscriptAugust 10, 2024 | seekingalpha.comNektar Therapeutics Q2 Loss Misses EstimatesAugust 9, 2024 | markets.businessinsider.comNektar Therapeutics Non-GAAP EPS of -$0.19, revenue of $23.49MAugust 9, 2024 | msn.comSee More Headlines NKTR Stock Analysis - Frequently Asked Questions How have NKTR shares performed this year? Nektar Therapeutics' stock was trading at $0.5650 at the start of the year. Since then, NKTR shares have increased by 123.0% and is now trading at $1.26. View the best growth stocks for 2024 here. How were Nektar Therapeutics' earnings last quarter? Nektar Therapeutics (NASDAQ:NKTR) announced its quarterly earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.21) by $0.04. The biopharmaceutical company earned $23.49 million during the quarter, compared to analyst estimates of $17.24 million. Nektar Therapeutics had a negative net margin of 190.09% and a negative trailing twelve-month return on equity of 133.64%. Who are Nektar Therapeutics' major shareholders? Nektar Therapeutics' top institutional shareholders include Samlyn Capital LLC (5.14%), Primecap Management Co. CA (3.27%), Acadian Asset Management LLC (2.65%) and Millennium Management LLC (2.53%). Insiders that own company stock include Deep Track Capital, Lp, Howard W Robin, Jillian B Thomsen, Gil M Labrucherie, Mark Andrew Wilson, Robert Chess, Jonathan Zalevsky, Roy A Whitfield, Myriam Curet and John Northcott. View institutional ownership trends. How do I buy shares of Nektar Therapeutics? Shares of NKTR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Nektar Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Nektar Therapeutics investors own include Micron Technology (MU), NVIDIA (NVDA), Alibaba Group (BABA), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/08/2024Today9/18/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals Current SymbolNASDAQ:NKTR CUSIP64026810 CIK906709 Webwww.nektar.com Phone(415) 482-5300Fax415-339-5300Employees220Year Founded1990Price Target and Rating Average Stock Price Target$1.50 High Stock Price Target$2.00 Low Stock Price Target$1.00 Potential Upside/Downside+19.0%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-276,060,000.00 Net Margins-190.09% Pretax Margin-190.17% Return on Equity-133.64% Return on Assets-42.03% Debt Debt-to-Equity RatioN/A Current Ratio5.15 Quick Ratio4.90 Sales & Book Value Annual Sales$93.16 million Price / Sales2.49 Cash FlowN/A Price / Cash FlowN/A Book Value$0.69 per share Price / Book1.83Miscellaneous Outstanding Shares184,020,000Free Float177,193,000Market Cap$231.87 million OptionableOptionable Beta0.60 Social Links Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:NKTR) was last updated on 9/18/2024 by MarketBeat.com Staff From Our PartnersThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored625,000% GainThe recent crypto correction has shaken many investors, causing panic and uncertainty. But while others are fr...Crypto Swap Profits | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nektar Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Nektar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.